Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy Datamonitor, Sep 2004, Pages: 89   Description     Table of Contents        Enquire before Buying    Send to a Friend   Introduction Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence exceeds that of HIV and is estimated at 2 billion infected individuals worldwide, accounting for approximately 5% of the world’s population. Scope Key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population Overview of the limitations surrounding co-morbid management such as recognition of co infection, high-risk groups and lack of efficacious antivirals Report Highlights Concurrent early diagnosis of both HIV and HBV disease states is pivotal to increasing the lifespan of this co-morbid population. Effective treatment is currently hampered by poor patient compliance, HAART hepatotoxicity and lack of comprehensive treatment guidelines. Reasons to Purchase Effectively target this niche sector, through a complete understanding of the prevalence of the co-morbid population in the seven major markets Identify the most promising products in the HIV and HBV pipelines, and track how current players are seeking to optimize their market share Scope Analysis based on interviews with key opinion leaders in the major markets Report Highlights Lack of potency with current HBV therapeutics is an obvious gap in treating both mono and co-infected patients currently being addressed by companies such as Gilead and Idenix/Novartis. Commercial support for global implementation of HBV vaccination need not preclude a high volume/low cost business model for a new potent HBV antiviral. Customers who bought this item also bought Stakeholder Opinions: HIV - Reaching the Untapped Patient Population Stakeholder Opinions: HIV/HCV Co-infection - Whose Niche? Stakeholder Insight: Anxiety Disorders - More Than Just a Comorbidity Stakeholder Opinions: HIV Vaccines - The Emperor Has No Clothes Hepatitis in China - Liver Let Die? HIV Update 2002 (6): June Pipeline Insight: HIV - Enter the New Generation Inhibitors Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster